UY32467A - Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh - Google Patents

Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh

Info

Publication number
UY32467A
UY32467A UY0001032467A UY32467A UY32467A UY 32467 A UY32467 A UY 32467A UY 0001032467 A UY0001032467 A UY 0001032467A UY 32467 A UY32467 A UY 32467A UY 32467 A UY32467 A UY 32467A
Authority
UY
Uruguay
Prior art keywords
groups
addition salts
acid derivatives
aminas
aminonicotinic acid
Prior art date
Application number
UY0001032467A
Other languages
English (en)
Inventor
Carrera Carrera Francesc
Juan Bautista Perez Garcia
Digna Jose Garcia Martin
Maria Carmen Boix Bernardini
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY32467A publication Critical patent/UY32467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevas sales de adición cristalinas, farmacéuticamente aceptables e hidrosolubles de (i) una amina que contiene uno o más grupos hidroxilo y/o carboxílicos con (ii) derivados de ácido aminonicotínicode fórmula (I). Donde Ra, Rb, Rc y Rd independientemente representan grupos seleccionados de átomos de hidrógeno, átomos de halógeno, grupos alquino C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o3 sustituyentes seleccionados de átomos de halógeno y grupos hidroxi, y sus solvatos farmacéuticamente.
UY0001032467A 2009-03-13 2010-02-24 Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh UY32467A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382031A EP2228367A1 (en) 2009-03-13 2009-03-13 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors

Publications (1)

Publication Number Publication Date
UY32467A true UY32467A (es) 2010-05-31

Family

ID=40677683

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032467A UY32467A (es) 2009-03-13 2010-02-24 Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh

Country Status (35)

Country Link
US (1) US20120014918A1 (es)
EP (2) EP2228367A1 (es)
JP (1) JP5674685B2 (es)
KR (1) KR101674699B1 (es)
CN (1) CN102348689B (es)
AR (1) AR075738A1 (es)
AU (1) AU2010223528B2 (es)
BR (1) BRPI1006766B8 (es)
CA (1) CA2754804C (es)
CL (1) CL2011002216A1 (es)
CO (1) CO6420337A2 (es)
CY (1) CY1114418T1 (es)
DK (1) DK2406225T3 (es)
EA (1) EA022350B1 (es)
EC (1) ECSP11011365A (es)
ES (1) ES2428746T3 (es)
HK (1) HK1162487A1 (es)
HR (1) HRP20130851T1 (es)
IL (1) IL214519A (es)
ME (1) ME01564B (es)
MX (1) MX2011009146A (es)
MY (1) MY155140A (es)
NZ (1) NZ594493A (es)
PE (1) PE20120171A1 (es)
PL (1) PL2406225T3 (es)
PT (1) PT2406225E (es)
RS (1) RS52949B (es)
SG (1) SG173823A1 (es)
SI (1) SI2406225T1 (es)
SM (1) SMT201300104B (es)
TW (1) TWI428127B (es)
UA (1) UA105786C2 (es)
UY (1) UY32467A (es)
WO (1) WO2010102826A1 (es)
ZA (1) ZA201105744B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
EP2594271A1 (en) * 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
KR101251851B1 (ko) 2011-11-30 2013-04-10 현대자동차주식회사 Ｉｓｇ 시스템 및 이의 제어방법
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP3308770A1 (en) * 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
EP3590920A4 (en) * 2017-03-02 2021-01-06 Shanghai Institute of Materia Medica, Chinese Academy of Sciences AROMATIC FORMIATE 2-FTO INHIBITOR (SUBSTITUTED BENZENE MATRIX), PROCESS OF PREPARATION AND APPLICATIONS
AU2019359036A1 (en) 2018-10-09 2021-06-03 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
KR20220035022A (ko) * 2018-12-21 2022-03-21 르 라보레또레 쎄르비에르 유기 화합물의 결정질 및 염 형태 및 그의 제약 조성물
EP4228640A1 (en) * 2020-10-15 2023-08-23 ASLAN Pharmaceuticals Pte Ltd Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
EP1225886A2 (en) * 1999-06-10 2002-07-31 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
SI1381356T1 (sl) 2001-04-05 2008-12-31 Aventis Pharma Inc Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP2004099586A (ja) * 2002-05-21 2004-04-02 Sumitomo Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害剤
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
CN1993125A (zh) 2004-05-21 2007-07-04 Uab研究基金会 涉及嘧啶合成抑制剂的组合物和方法
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
EP1804782A1 (en) 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
PL2406225T3 (pl) 2013-12-31
MY155140A (en) 2015-09-15
HRP20130851T1 (hr) 2013-10-25
TWI428127B (zh) 2014-03-01
ZA201105744B (en) 2012-04-25
AR075738A1 (es) 2011-04-20
CN102348689B (zh) 2014-05-14
PE20120171A1 (es) 2012-03-01
KR20110126694A (ko) 2011-11-23
IL214519A (en) 2015-03-31
HK1162487A1 (en) 2012-08-31
CL2011002216A1 (es) 2012-03-09
IL214519A0 (en) 2011-09-27
DK2406225T3 (da) 2013-09-30
CN102348689A (zh) 2012-02-08
EP2406225A1 (en) 2012-01-18
TW201034669A (en) 2010-10-01
US20120014918A1 (en) 2012-01-19
JP2012520252A (ja) 2012-09-06
WO2010102826A1 (en) 2010-09-16
BRPI1006766B8 (pt) 2021-05-25
ES2428746T3 (es) 2013-11-11
EA022350B1 (ru) 2015-12-30
BRPI1006766B1 (pt) 2021-03-23
UA105786C2 (uk) 2014-06-25
AU2010223528A1 (en) 2011-08-25
MX2011009146A (es) 2011-09-15
CY1114418T1 (el) 2016-08-31
JP5674685B2 (ja) 2015-02-25
PT2406225E (pt) 2013-09-19
AU2010223528B2 (en) 2017-02-16
SG173823A1 (en) 2011-09-29
EA201101297A1 (ru) 2012-04-30
RS52949B (en) 2014-02-28
EP2406225B1 (en) 2013-06-26
CA2754804A1 (en) 2010-09-16
EP2228367A1 (en) 2010-09-15
KR101674699B1 (ko) 2016-11-09
CA2754804C (en) 2018-07-24
ME01564B (me) 2014-09-20
ECSP11011365A (es) 2011-10-31
SMT201300104B (it) 2013-11-08
CO6420337A2 (es) 2012-04-16
SI2406225T1 (sl) 2013-10-30
NZ594493A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
UY32467A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
IN2014CN00473A (es)
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO7400872A2 (es) Derivados sustituidos de ftalazin-1(2h)-ona
AU2011209274A8 (en) Substituted naphthyridines and their use as Syk kinase inhibitors
UY33883A (es) Novedosos derivados heterocíclicos
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
IN2014CN04530A (es)
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MX2012003982A (es) Pirrolidinas n-substituidas.
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
UA107784C2 (en) Inhibitor of melanin production
MX353190B (es) Derivados de isoquinolina y naftiridina.
UA107689C2 (en) 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
AR092772A1 (es) Derivado de 7-azaindol
MX2013003498A (es) Derivados de cromeno.
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
CU20110012A7 (es) Derivados de heteroarilo como inhibidores de dgat1
MA35510B1 (fr) Composés de pyridazinon et leur utilisation en tant qu'inhibiteurs de la daao
LV14984A (lv) 2-Fenilamino-4-(piridīn-3-il)-6-perfluoralkilpirimidīni

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20210609